HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

504.495

+4.5040.90%

Number of Gainers:16

Number of Losers:14

Number of Flat:4

PE:- -

High:505.313

Open:500.023

Low:490.944

Close:499.991

Loading ...

Immunotech Biopharm Ltd. Announces Resignation of CEO and CTO, Appoints Acting CEO

Immunotech Biopharm - Wang Yu Resigns as CEO and Executive Director

THOMSON REUTERS

Immunotech Biopharm Ltd - Zhang Jian Appointed as Acting CEO

THOMSON REUTERS

Venus MedTech Hangzhou Inc. Announces Re-election and Appointment of New Directors and Supervisors for the Third Session

Zai Lab Ltd. to Participate in Jefferies Global Healthcare Conference Fireside Chat

Zylox-Tonbridge Medical Technology Co. Ltd. Convened Annual General Meeting

Zylox-Tonbridge Medical Technology Co. Ltd. Announces Final Dividend of RMB 0.1 Per Share for Year Ended 31 December 2024

Acotec Scientific Holdings Ltd - Approval for Peripheral Thrombus Separation Stent by PRC Nmpa

THOMSON REUTERS

Alphamab Oncology Announces New Compensation Plan with Award Shares for Directors

SinoMab BioScience Ltd. Completes New Share Subscriptions Under General Mandate

Acotec Scientific Holdings Ltd. Secures PRC National Medical Products Administration Approval for E-Peridge® Peripheral Scoring Balloon Dilatation Catheter

Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer

Genor Biopharma - Nmpa Granted New Drug Application Approval for Lerociclib (Gb491)

THOMSON REUTERS

Acotec Scientific - Approval for Peripheral Scoring Balloon Dilatation Catheter E-Peridge by Nmpa

THOMSON REUTERS

HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 500,000 Shares at HKD 4,166,000

Zylox-Tonbridge Files Next Day Disclosure with HKEX: Announces 80,000 Shares Repurchased at HKD 1,456,480

TOT BIOPHARM Rebrands to BioDlink International

JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment

JW (Cayman) Therapeutics - Nmpa Acceptance of Supplemental Biological License Application for Carteyva

THOMSON REUTERS

CARsgen Therapeutics' Satricabtagene Autoleucel Granted Priority Review by China's NMPA for Advanced Gastric Cancer Therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":504.49472,"timestamp":1749197315343,"preClose":499.99072,"halted":0,"volume":133942207,"delay":0,"changeRate":0.009008,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.503998,"latestTime":"06-06 16:00:00","open":500.0226,"high":505.3134,"low":490.94357,"amount":2424247939,"amplitude":0.02874,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":4.156734,"peRate":-25.602863,"turnoverRate":0.005008,"increases":16,"decrements":13,"flats":4,"marketCap":294601588992,"floatMarketCap":270286158640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.3134,"amplitude":0.02874,"preClose":499.99072,"low":490.94357,"pbRate":"4.156734","latestPrice":504.49472,"volume":133942207,"delay":0,"open":500.0226,"prevYearClose":331.1933,"prevWeekClose":491.683,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":491.683,"twentyDayClose":458.671,"sixtyDayClose":437.197,"secType":"PLATE","market":"HK","turnoverRate":0.005008,"peRate":-25.602863,"marketCap":294601588992,"floatMarketCap":270286158640,"timestamp":1749197315343,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":16,"down":14,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539278792","title":"Immunotech Biopharm Ltd. Announces Resignation of CEO and CTO, Appoints Acting CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2539278792","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539278792?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:05","pubTimestamp":1748613941,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm Ltd. has announced that Dr. Wang Yu has resigned from her roles as executive director, chief executive officer, and chief technology officer, effective June 25, 2025. Mr. Zhang Jian, the senior vice president, has been appointed as the Acting CEO to manage the day-to-day operations of the company. The board has denied any merit to recent allegations made by Dr. Wang and reports no disagreements with other directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunotech Biopharm Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL852Nxx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2539278231","title":"Immunotech Biopharm - Wang Yu Resigns as CEO and Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2539278231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539278231?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:02","pubTimestamp":1748613737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2539235278","title":"Immunotech Biopharm Ltd - Zhang Jian Appointed as Acting CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2539235278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539235278?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:02","pubTimestamp":1748613737,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S230G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2539221097","title":"Venus MedTech Hangzhou Inc. Announces Re-election and Appointment of New Directors and Supervisors for the Third Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221097","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539221097?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:51","pubTimestamp":1748605879,"startTime":"0","endTime":"0","summary":"Venus MedTech HangZhou Inc. has announced the re-election and appointment of directors and supervisors for the third session of its Board and Supervisory Committee. The current executive directors are Lim Hou-Sen, Liqiao Ma, and Meirong Liu. The non-executive directors include Ao Zhang and Wei Wang, while the independent non-executive directors are Ting Yuk Anthony Wu, Chi Wai Suen, and John Junhua Gu.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL5L052x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","02500","BK1100"],"gpt_icon":0},{"id":"2539522150","title":"Zai Lab Ltd. to Participate in Jefferies Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2539522150","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539522150?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:30","pubTimestamp":1748604613,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd. will participate in the Jefferies Global Healthcare Conference with a fireside chat scheduled for Wednesday, June 4, 2025, at 10:30 a.m. EST in New York, NY. A live webcast of the event will be available on Zai Lab's Investor Relations page.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire  on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL2mvQWv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1588","BK1574","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2539226475","title":"Zylox-Tonbridge Medical Technology Co. Ltd. Convened Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226475?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:46","pubTimestamp":1748602017,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. held its 2024 Annual General Meeting on May 30, 2025. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL3Ct7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","BK1574","BK1100","02190"],"gpt_icon":0},{"id":"2539226990","title":"Zylox-Tonbridge Medical Technology Co. Ltd. Announces Final Dividend of RMB 0.1 Per Share for Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226990?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:45","pubTimestamp":1748601905,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has announced a final dividend of RMB 0.1 per share for the financial year ending 31 December 2024. The dividend will be paid in Hong Kong dollars at a rate of HKD 0.1089909 per share, following an updated exchange rate. Shareholders' approval for this dividend was obtained on 30 May 2025, with the payment date set for 27 June 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL3jQvgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1100","BK1583","BK1574","02190"],"gpt_icon":0},{"id":"2539249780","title":"Acotec Scientific Holdings Ltd -  Approval for Peripheral Thrombus Separation Stent by PRC Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539249780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539249780?lang=en_us&edition=fundamental","pubTime":"2025-05-30 16:31","pubTimestamp":1748593899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S12YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06669","BK1587","BK1100","BK1574"],"gpt_icon":0},{"id":"2539324257","title":"Alphamab Oncology Announces New Compensation Plan with Award Shares for Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2539324257","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539324257?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:44","pubTimestamp":1748519056,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has announced the grant of award shares under its Restricted Share Award Scheme, as disclosed in a recent filing with The Stock Exchange of Hong Kong Limited. The company aims to recognize and reward the contributions of its Award Directors, providing them with shares as part of their compensation. The shares granted to the Award Directors do not have specific performance targets, aligning with the company's remuneration policy. This initiative is part of the company's efforts to closely align the interests of its shareholders, the company, and its directors. The announcement, made by Chairman Dr. Xu Ting, highlights the company's focus on its continual operation and long-term growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL75ZkzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"2539225430","title":"SinoMab BioScience Ltd. Completes New Share Subscriptions Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2539225430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539225430?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:55","pubTimestamp":1748516156,"startTime":"0","endTime":"0","summary":"SinoMab BioScience Ltd. has successfully completed the issuance of new shares under a general mandate. The completion of the share subscription took place after fulfilling the conditions set out in the Subscription Agreements. An aggregate of 112,810,817 new shares were issued, which now represent 9.37% of the total shares. This strategic move has adjusted the shareholdings, with notable stakeholders such as the Apricot Entities, Hainan Haiyao Co., Ltd., and Skytech Technology Limited seeing changes in their respective shareholding percentages. Skytech Technology Limited is wholly owned by Dr. Shui On Leung, the executive director and chairman of SinoMab. The company is focused on advancing its business objectives with the support of these new capital inflows.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5vLTwf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000566","BK1161","BK0060","BK0070","BK1574","BK0188","BK0239","03681","BK0146"],"gpt_icon":0},{"id":"2539237202","title":"Acotec Scientific Holdings Ltd. Secures PRC National Medical Products Administration Approval for E-Peridge® Peripheral Scoring Balloon Dilatation Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2539237202","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539237202?lang=en_us&edition=fundamental","pubTime":"2025-05-29 17:02","pubTimestamp":1748509374,"startTime":"0","endTime":"0","summary":"Acotec Scientific Holdings Ltd. Secures PRC National Medical Products Administration Approval for E-Peridge Peripheral Scoring Balloon Dilatation Catheter. Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Peripheral Scoring Balloon Dilatation Catheter, E-Peridge. This approval, granted on May 27, 2025, marks a significant milestone for the company as it enhances its product portfolio aimed at treating stenotic lesions in peripheral vessels, including the iliac and renal arteries. The E-Peridge catheter is designed to provide effective anchoring and reduce elastic recoil of plaques, thus minimizing vascular injury. Acotec plans to initiate marketing activities in the PRC market, although the company cautions that successful commercialization is not guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5Rrg1J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU1989772923.USD","LU0011850046.USD","LU0882574055.USD","LU2087625088.SGD","LU2244417387.USD","LU1023059063.AUD","LU1153585028.USD","LU0345769128.USD","BSX","LU0187121727.USD","LU2362541513.USD","LU0251132253.USD","LU2506952170.USD","BK4585","LU2324357040.USD","LU1983299246.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU2506952097.USD","LU2362541273.HKD","LU0266013472.USD","LU0345769631.USD","LU0077335932.USD","LU0823417737.USD","IE00B2B36J28.USD","BK4504","LU1057294990.SGD","LU2362540622.SGD","BK1574","LU0225283273.USD","LU0238689110.USD","LU1291159041.SGD","BK4588","LU1989764748.USD","IE0009355771.USD","LU1989771016.USD","LU1804176565.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU2112291526.USD","LU2491050071.SGD","BK1100","LU1366192091.USD","IE0002141913.USD","LU1791710400.SGD","LU0267386448.USD","LU1791710582.SGD","06669","LU0048584097.USD"],"gpt_icon":0},{"id":"2539723716","title":"Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539723716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539723716?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:59","pubTimestamp":1748509188,"startTime":"0","endTime":"0","summary":"Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration  has granted approval for the new drug application of Lerociclib . This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor  has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative  locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL8XC61z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","06998"],"gpt_icon":0},{"id":"2539376982","title":"Genor Biopharma - Nmpa Granted New Drug Application Approval for Lerociclib (Gb491)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539376982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539376982?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:48","pubTimestamp":1748508491,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S10H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1574","06998"],"gpt_icon":0},{"id":"2539237367","title":"Acotec Scientific -  Approval for Peripheral Scoring Balloon Dilatation Catheter E-Peridge by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2539237367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539237367?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:42","pubTimestamp":1748508174,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S1064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1100","BK1587","06669"],"gpt_icon":0},{"id":"2538475138","title":"HBM Holdings Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 500,000 Shares at HKD 4,166,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2538475138","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538475138?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:16","pubTimestamp":1748434581,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 500,000 shares. The shares were repurchased at a price of HKD 8.332 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL2RKhK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2538473046","title":"Zylox-Tonbridge Files Next Day Disclosure with HKEX: Announces 80,000 Shares Repurchased at HKD 1,456,480","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473046","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473046?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:01","pubTimestamp":1748433695,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, detailing the repurchase of 80,000 shares to be held as treasury shares. The aggregate price paid for the repurchase was HKD 1,456,480.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL44Km65:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","02190","BK1583","BK1587"],"gpt_icon":0},{"id":"2538420805","title":"TOT BIOPHARM Rebrands to BioDlink International","url":"https://stock-news.laohu8.com/highlight/detail?id=2538420805","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538420805?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:50","pubTimestamp":1748429458,"startTime":"0","endTime":"0","summary":"TOT BIOPHARM International Co. Ltd. has announced a name change to BioDlink International Company Limited. This change was outlined in a recent report issued by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL78DF9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875","BK1574","BK1161"],"gpt_icon":0},{"id":"2538423760","title":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2538423760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538423760?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:57","pubTimestamp":1748422651,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment. JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China  has accepted the supplemental Biological License Application  for Carteyva . The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma  who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLbrjft9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2538428296","title":"JW (Cayman) Therapeutics - Nmpa Acceptance of Supplemental Biological License Application for Carteyva","url":"https://stock-news.laohu8.com/highlight/detail?id=2538428296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538428296?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:35","pubTimestamp":1748421322,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","02126","BK1161"],"gpt_icon":0},{"id":"2538331448","title":"CARsgen Therapeutics' Satricabtagene Autoleucel Granted Priority Review by China's NMPA for Advanced Gastric Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2538331448","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538331448?lang=en_us&edition=fundamental","pubTime":"2025-05-28 12:06","pubTimestamp":1748405164,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL3cBrCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":69,"code":"91000000","status":"200"}]}}